Gilead Sciences, Inc.

Gilead Pharmasset LLC

Schlumberger Canada Limited

Ruben Martinez

Jeff A Zablocki

Britton Kenneth Corkey

Robert H Jiang

Tetsuya Kobayashi

Elfatih O Elzein

Michael Graupe

Chandrasekar Venkataramani

Rao V Kalla

Thao Perry

Xiaofen Li

Dmitry Koltun

Juan A Guerrero

Eric Q Parkhill

James G Taylor

Dustin S Siegel

Darryl Kato

Adam James Schrier

Michael Sangi

Kapil Kumar Karki

John O Link

Hyung-Jung Pyun

Jeromy J Cottell

Zheng-Yu Yang

Barton W Phillips

Sheila M Zipfel

Eda Y Canales

Chinh Viet Tran

Teresa Alejandra Trejo Martin

Randall W Vivian

Ashley Anne Katana

Gregory Notte

Jinfa Du

Samuel E Metobo

Michael R Mish

David Sperandio

Hai Yang

Gregory F Chin

Evangelos Aktoudianakis

Kristyna M Elbel

Kyla Bjornson

Sophie Shevick

Rick Andrew Lee

Bruce Ross

Nathan D Shapiro

Jonathan Clive Tripp

Katie Ann Keaton

Andrew W Waltman

Troy Evan Reynolds

Denise A Colby

Manuel Munoz

Johann Chan

Dominika Pcion

Lina Chan

Donald Tang

Amy Cagulada

Chris Levins

Adam Littke

Pamela Seng

Lawrence Yu

Wade D Dupree

Kyla Ramey

Sudha Kondappally

Sudha Kondapally

Troy Reynolds

Jonathan Tripp

Pierre-Arnaud Foucher

Compounds of Formula I are disclosed  As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.

Inhibitors of hepatitis C virus

Compounds of Formula I are disclosed As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.

The present disclosure provides processes for the preparation of a compound of formula I: which is useful as an antiviral agent. The disclosure also provides compounds and processes for the preparation of the compounds that are synthetic intermediates to the compound of formula I.

Synthesis of an antiviral compound

This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R, R, R, R, R, R, R, and Rare described herein.

Benzimidazole derivatives as bromodomain inhibitors

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Y, Z, n, Rand Rare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

Fused heterocyclic compounds as ion channel modulators

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Q, R, X, X, Y and Rare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Z, Z, Z, Z, X, Y, R, Rand Rare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R, R, R, R, R, and X are described herein.

Benzimidazolone derivatives as bromodomain inhibitors

Growing community of inventors

San Diego, CA, United States of America

Ruben Martinez